• Merck initiates three Phase III trials into Keytruda for prostate cancer

  As a result of promising data from its Phase Ib/II KEYNOTE-365 trial, Merck has announced...
  Read More...

• SK Biopharmaceuticals-Arvelle partner on epilepsy drug cenobamate in Europe

  South Korea-based SK Biopharmaceuticals and Swiss Arvelle Therapeutics have signed an exclusive licensing agreement to...
  Read More...

• Erectile dysfunction: giving patients more choice and better treatments

  Erectile dysfunction affects around 50% of men between 40 and 70 years old. Futura Medical...
  Read More...

• AbCellera and Novartis enter into multi-target partnership

  Canada-based AbCellera has announced it has signed a multi-year, multi-target agreement with Novartis under which...
  Read More...

• National Heart Month: how can you heal a broken heart?

  February is National Heart Month in the US and the US, which focuses on raising...
  Read More...

• MHRA recalls a further three batches of sartan-based products

  The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has announced it has recalled three...
  Read More...

• Dementia Consortium welcomes new partners to drug discovery collaboration

  Charity industry partnership Dementia Consortium has announced that pharmaceutical companies, Johnson & Johnson Innovation, Takeda...
  Read More...

• Top ten healthcare sector M&A financial and legal advisers for 2018

  Morgan Stanley has topped the latest M&A league table of the top ten financial advisers...
  Read More...

• FDA grants Merck’s Keytruda priority review as first line therapy for HNSCC

  Merck has announced the US Food and Drug Administration (FDA) has granted priority review for...
  Read More...

• FDA clamps down on illegal dietary supplements

  The US Food and Drug Administration (FDA) has announced new measures to strengthen its regulation...
  Read More...